Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China.
Department of Pathophysiology, Key Laboratory of Pathophysiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130041, P.R. China.
Oncol Rep. 2021 Feb;45(2):513-522. doi: 10.3892/or.2020.7879. Epub 2020 Dec 2.
Ovarian cancer is a gynecological malignancy with high mortality. Adjuvant therapy such as chemoradiotherapy inevitably leads to side effects and drug resistance. In recent years, traditional Chinese medicine has been widely studied for its safety, effectiveness, and unique pharmacological effects. Polyphyllin VII is an important component of Rhizoma paridis saponins, and has cytotoxic effects on many types of cancer cells. The aim of the present study was to evaluate the anti‑tumor activity of polyphyllin VII in human ovarian cancer cells. Recent studies found that polyphyllin VII induces mitochondrial pathway apoptosis by increasing mitochondrial division, but the specific mechanism was unclear. The results of this study revealed that polyphyllin VII could effectively induce mitochondrial dysfunction, including increased mitochondrial division and reactive oxygen species (ROS) production. Notably, the mitochondrial location of dynamin‑related protein 1 (DRP1) plays an important role in its function. In addition, polyphyllin VII enhanced the mitochondrial localization of DRP1 which is mediated by increased protein phosphatase 2A (PP2A) activity, and decreased AKT activity. A specific PP2A inhibitor, LB100, attenuated mitochondrial division and apoptosis in cells caused by polyphyllin VII, confirming the function of the PP2A/AKT pathway in polyphyllin VII treatment. Additionally, xenotransplantation experiments have also confirmed the anti‑tumor effect of polyphyllin VII in vivo. Therefore, interference of the mitochondrial translocation of DRP1 through PP2A/AKT pathway may be an attractive and effective therapeutic approach by polyphyllin VII in ovarian cancer. This may provide new strategies for polyphyllin VII in the clinical treatment of ovarian cancer.
卵巢癌是一种死亡率较高的妇科恶性肿瘤。辅助治疗如放化疗不可避免地会导致副作用和耐药性。近年来,中药因其安全性、有效性和独特的药理作用而得到广泛研究。重楼七叶一枝花苷是重楼属植物皂苷的重要组成部分,对多种癌细胞具有细胞毒性作用。本研究旨在评估重楼七叶一枝花苷在人卵巢癌细胞中的抗肿瘤活性。最近的研究发现,重楼七叶一枝花苷通过增加线粒体分裂诱导线粒体途径凋亡,但具体机制尚不清楚。本研究结果表明,重楼七叶一枝花苷能有效诱导线粒体功能障碍,包括增加线粒体分裂和活性氧(ROS)的产生。值得注意的是,动力相关蛋白 1(DRP1)的线粒体定位在其功能中起着重要作用。此外,重楼七叶一枝花苷增强了 DRP1 的线粒体定位,这是由蛋白磷酸酶 2A(PP2A)活性增加和 AKT 活性降低介导的。一种特异性的 PP2A 抑制剂 LB100 减弱了重楼七叶一枝花苷引起的细胞线粒体分裂和凋亡,证实了 PP2A/AKT 通路在重楼七叶一枝花苷治疗中的作用。此外,异种移植实验也证实了重楼七叶一枝花苷在体内的抗肿瘤作用。因此,通过 PP2A/AKT 通路干扰 DRP1 的线粒体易位可能是重楼七叶一枝花苷治疗卵巢癌的一种有吸引力和有效的治疗方法。这可能为重楼七叶一枝花苷在卵巢癌的临床治疗中提供新的策略。